Trial Details 106 Total Sites

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.

phase

Phase 3

status

Recruiting

enrollment

1700

score

57

start date

2021-05-04

last updated

2021-09-13

Jacksonville, Florida
facility
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
1 facility
Recruiting
Portland, Oregon
facility
Providence Health & Services - Oregon
1 facility
Recruiting
Baltimore, Maryland
facility
University of Maryland Medical Center
facility
Greater Baltimore Med Ctr; Dept Berman Cancer Institute
+1 more facilities
3 facilities
Recruiting
Nashville, Tennessee
facility
Tennessee Oncology; Sarah Cannon Research Institute
1 facility
Recruiting
Fresno, California
facility
California Cancer Associate for Research & Excellence
1 facility
Recruiting
Virginia Beach, Virginia
facility
Virginia Oncology Associates - Virginia Beach
1 facility
Recruiting
Norfolk, Virginia
facility
Virginia Oncology Associates
1 facility
Recruiting
Richmond, Virginia
facility
Virginia Cancer Institute
1 facility
Recruiting
Tacoma, Washington
facility
Northwest Medical Specialties
1 facility
Recruiting
Knoxville, Tennessee
facility
Thompson Cancer Survival Center
1 facility
Recruiting
Newport News, Virginia
facility
Virginia Oncology Associates - New Port News
1 facility
Recruiting
Chattanooga, Tennessee
facility
SCRI Tennessee Oncology Chattanooga
1 facility
Recruiting